Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis

Annals of the New York Academy of Sciences

Volumn 1130, Issue , 2008, Pages 280-286

  Diermeier Daucher, Simone ^a   Hasmann, Max ^b   Brockhoff, Gero ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Breast cancer; c erbB2 homodimerization; FCET; Flow cytometry; FRET; Pertuzumab; Receptor interaction; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOMODIMER; MONOCLONAL ANTIBODY; PERTUZUMAB; TRASTUZUMAB;

BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DIMERIZATION; DRUG BINDING; DRUG POTENCY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

EID: 47249112974     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1430.003     Document Type: Conference Paper

References (30)

1. Brockhoff, G., P. Heiss, et al. 2001. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 44 : 338 348.
2. Diermeier, S., G. Horvath, et al. 2005. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell Res. 304 : 604 619.
3. Nagy, P., L. Bene, et al. 1998. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements. Cytometry 32 : 120 131.
4. Schmid, J.A. & H.H. Sitte. 2003. Fluorescence resonance energy transfer in the study of cancer pathways. Curr. Opin. Oncol. 15 : 55 64.
5. Tron, L., J. Szollosi, et al. 1984. Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis. Biophys. J. 45 : 939 946.
6. Graus-Porta, D., R.R. Beerli, et al. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16 : 1647 1655.
7. Yarden, Y. & M.X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2 : 127 137.
8. Zaczek, A., B. Brandt, et al. 2005. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol. Histopathol. 20 : 1005 1015.
9. Slamon, D.J., G.M. Clark, et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 : 177 182.
10. Adams, C.W., D.E. Allison, et al. 2006. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, Pertuzumab. Cancer Immunol. Immunother. 55 : 717 727.
11. Albanell, J., J. Codony, et al. 2003. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532 : 253 268.
12. Molina, M.A., R. Saez, et al. 2002. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8 : 347 353.
13. Agus, D.B., R.W. Akita, et al. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2 : 127 137.
14. Baselga, J. 2002. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell. 2 : 93 95.
15. Diermeier-Daucher, S. & G. Brockhoff. 2007. Flow cytometric FRET analysis of (erbB-) receptor-tyrosine-kinase interaction. Submitted to Current Protocols in Cytometry.
16. Szentesi, G., G. Vereb, et al. 2005. Computer program for analyzing donor photobleaching FRET image series. Cytometry A. 67 : 119 128.
17. Brockhoff, G., B. Heckel, et al. 2007. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 40 : 488 507.
18. Diermeier, S., E. Schmidt-Bruecken, et al. 2004. Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell lines. Cell Prolif. 37 : 195 206.
19. Kubbies, M. 1999. High-resolution cell cycle analysis: the flow cytometric bromodeoxyuridine-Hoechst quenching technique. In Flow Cytometry and Cell Sorting, 2nd ed. A. Radbruch, Ed., 2nd ed., pp. 112 124. Springer. Berlin, Heidelberg, New York.
20. Sebestyen, Z., P. Nagy, et al. 2002. Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer. Cytometry 48 : 124 135.
21. Cho, H.S., K. Mason, et al. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 : 756 760.
22. Badache, A. & N.E. Hynes. 2004. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell. 5 : 299 301.
23. Pal, S.K. & M. Pegram. 2006. Targeting HER2 Epitopes. Sem. Oncol. 33 : 386 389.
24. Mass, R.D., M.F. Press, et al. 2005. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with Trastuzumab. Clin. Breast Cancer 6 : 240 246.
25. Christianson, T.A., J.K. Doherty, et al. 1998. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58 : 5123 5129.
26. Zabrecky, J.R., T. Lam, et al. 1991. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 266 : 1716 1720.
27. Nahta, R., M.C. Hung, et al. 2004. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64 : 2343 2346.
28. Jones, R.B., A. Gordus, et al. 2006. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439 : 168 174.
29. Schulze, W., L. Deng, et al. 2005. Phosphoryrosine interactome of the ErbB-receptor kinase family. Molecular Systems Biology, EMBO and Nature Publishing Group. 1 : 2005.0008.
30. Sassen, A., J. Rochon, et al. 2007. Cytogenetic analysis of HER1/EGFR, HER2, HER3, and HER4 in 278 breast cancer patients. Breast Cancer Res. submitted Labeling scheme for flow cytometric c-erbB2 homodimerization assessment with FRET. Trastuzumab (A) or pertuzumab (B) treated FRET samples were stained separately with Cy3 (donor dye) and Cy5 (acceptor dye) conjugated pertuzumab (A) or trastuzumab (B), respectively.